A wave of new clinical data on retatrutide — the investigational triple agonist drug developed by Eli Lilly — was presented at the American Diabetes Association (ADA) annual meeting in New Orleans, drawing significant attention from the endocrinology and obesity medicine communities. Full results from two separate retatrutide trials were shared: one evaluating the drug in treatment-naive patients with type 2 diabetes, and a second in patients living with obesity. The data, now available via a peer-reviewed publication, offers the clearest picture yet of how retatrutide performs across both metabolic conditions.
In the type 2 diabetes trial, retatrutide demonstrated meaningful reductions in blood sugar alongside substantial weight loss — a dual benefit that sets it apart from many older diabetes therapies that address glucose control but contribute little to body weight reduction. Treatment-naive patients with type 2 diabetes showed clinically significant HbA1c lowering along with body weight reductions that rival or exceed what has historically been achieved with dedicated weight loss medications. These findings underscore retatrutide's potential as a single agent capable of addressing both the glycemic and adiposity dimensions of metabolic disease.
It is important to note that the pivotal Phase 2 obesity trial (NCT04881760, published in the New England Journal of Medicine in 2023) specifically excluded patients with type 2 diabetes, defined as HbA1c ≥6.5% or fasting glucose ≥126 mg/dL. The newly presented ADA data therefore fills a critical gap, extending the evidence base to the population most likely to carry both diagnoses simultaneously.
Retatrutide — commonly referred to as reta in patient communities — works through a mechanism that distinguishes it from every other approved obesity or diabetes medication currently on the market. While semaglutide targets a single receptor (GLP-1) and tirzepatide targets two (GLP-1 and GIP), retatrutide simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This makes it a true triple agonist — sometimes called "triple G" in online patient communities — and each receptor contributes a distinct metabolic effect.
This tri-receptor synergy appears to translate into results that exceed those of dual or single agonists. In the Phase 2 obesity trial, participants receiving 8 mg once weekly achieved a mean weight loss of approximately 22.8% at 48 weeks, with 100% of participants in that dose group achieving at least 5% weight loss and up to 70% achieving at least 20% weight loss. Cardiometabolic markers also improved substantially: triglycerides fell by as much as 39.3% at 24 weeks in the 8 mg group, and LDL cholesterol declined by 15.6–16.9%.
For patients with type 2 diabetes, glucagon receptor agonism adds another dimension: by increasing hepatic glucose output acutely, glucagon may seem counterintuitive in a diabetes drug — but when paired with GLP-1 and GIP activity, the net effect on blood glucose is favorable, and the metabolic boost to fat burning may provide additional benefit in insulin-resistant states.
| Drug | Receptor Targets | Phase 3 Mean Weight Loss | Trial Duration |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | GLP-1 | ~14.9% | 68 weeks (STEP-1) |
| Tirzepatide 15 mg (Zepbound) | GLP-1 + GIP | ~20.9% | 72 weeks (SURMOUNT-1) |
| Retatrutide 12 mg | GLP-1 + GIP + Glucagon | 28.7% | 68 weeks (TRIUMPH-4) |
The TRIUMPH-4 Phase 3 trial — Lilly's landmark study released in December 2025 — reported a mean weight loss of 28.7% at the 12 mg dose over 68 weeks, the highest figure ever recorded in a Phase 3 obesity trial. To put that into perspective, a patient starting at 250 lbs could expect to lose approximately 72 lbs on average. The titration schedule used in TRIUMPH-4 began at 2 mg and stepped up gradually every four weeks, reaching the 12 mg maintenance dose at week 17 — a careful approach designed to minimize gastrointestinal side effects during dose escalation.
Side effects in Phase 2 and Phase 3 data are consistent with the GLP-1 class: nausea, diarrhea, and vomiting are the most commonly reported, are dose-dependent, and peak during the titration period. A notable signal specific to retatrutide is dysesthesia — abnormal skin sensations — which occurred in 20.9% of participants at the 12 mg dose in TRIUMPH-4, compared with 0.7% on placebo. This finding is being closely monitored as the Phase 3 program matures.
As of April 2026, Eli Lilly has not yet filed a New Drug Application (NDA) with the FDA for retatrutide, and no approval timeline has been publicly confirmed. The TRIUMPH-4 Phase 3 trial results are compelling, but the peer-reviewed Phase 3 publication remains pending. The new ADA data extending retatrutide's evidence base into type 2 diabetes is particularly significant from a regulatory standpoint: if Lilly pursues an indication that includes patients with type 2 diabetes — a population excluded from Phase 2 — this trial data would form part of the evidentiary foundation for that label expansion.
Regulatory review typically follows NDA submission by 12 months or more under standard review, though priority review designation could shorten that timeline. Given the magnitude of the weight loss outcomes observed and the unmet need in both obesity and type 2 diabetes, retatrutide will likely receive considerable scrutiny — and considerable attention — as it moves through the approval process.
For patients and clinicians tracking this space, the convergence of Phase 3 weight loss data, new type 2 diabetes trial results, and a growing body of cardiometabolic evidence makes the coming 12–18 months a pivotal window for retatrutide's development story.
If you are interested in staying informed as retatrutide moves through the FDA review process, glp3md.com maintains an active waitlist for individuals who want to be notified as new clinical data and availability information becomes public. Joining the waitlist costs nothing and carries no obligation. Please note: retatrutide is not FDA-approved, and joining the waitlist does not guarantee access to medication, a prescription, or any form of treatment. The waitlist is for informational purposes only. Visit https://www.glp3md.com to add your name and receive updates as this rapidly evolving field continues to develop.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.